Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01129648 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate sUA-Lowering Activity, Safety & PK Interaction of Oral BCX4208 & Allopurinol Admin. in Subjects w/Gout
A Phase 2 study, sponsored by BioCryst Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 87
- Enrollment target
NCT01129648: Completed Phase 2 study, sponsored by BioCryst Pharmaceuticals.
NCT01129648 is a Phase 2 study that has completed, run by BioCryst Pharmaceuticals. The registered enrollment target is 87 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (35% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01129648, a Phase 2 study, has completed, sponsored by BioCryst Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 87 participants
- Enrollment target
Study Summary
To evaluate safety and efficacy of BCX4208 alone and in combination with allopurinol in subjects with gout.
Interventions
- DRUG Placebo
- DRUG Allopurinol
- DRUG BCX4208
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 87 participants |
| Start Date | 2010-05 |
| Est. Completion | 2010-11 |
| Phase | Phase 2 |
What the finished NCT01129648 record still lists
NCT01129648 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 87 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (35% lower).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01129648 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01129648 about?
NCT01129648 is a clinical study titled "Study to Evaluate sUA-Lowering Activity, Safety & PK Interaction of Oral BCX4208 & Allopurinol Admin. in Subjects w/Gout". To evaluate safety and efficacy of BCX4208 alone and in combination with allopurinol in subjects with gout.
What is the current status of trial NCT01129648?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 87 participants. The study started on 2010-05. Estimated completion is 2010-11.
What interventions are being tested in trial NCT01129648?
The interventions under investigation include: Placebo (DRUG), Allopurinol (DRUG), BCX4208 (DRUG).
Who is sponsoring clinical trial NCT01129648?
This trial is sponsored by BioCryst Pharmaceuticals, which has 29 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01129648's enrollment target sits among peer trials
87 810th of 2000 higher than 1,189 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03292601 · 87 participants · NA
Brace Monitoring for Adolescent Idiopathic Scoliosis (AIS)
- NCT04291105 · 87 participants · Phase 2
Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients
- NCT04565795 · 87 participants · NA
Safety and Device Performance of the Uriprene® Degradable Temporary Ureteral Stent Following Uncomplicated Ureteroscopy
- NCT05607004 · 87 participants · Phase 2
(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia